Psoriasis

At present, deployed members of the military are not permitted to be receiving therapy with systemic therapies such as immunomodulators and biologics.

Last week, the US Food and Drug Administration approved biosimilar ustekinumab-aekn (Selarsdi; Alvotech and Teva) for psoriasis and PsA.

A recent review and meta-analysis says this statistic may be due in part to nocebo effects.

Data stems from week 28 results of the German G-EPOSS study evaluating the effectiveness of guselkumab in skin health, quality of life, sexuality, and stigmatization.

Risankizumab demonstrated the highest efficacy in PASI90 responses among analyzed IL-23 inhibitors.

Experts in dermatology share closing thoughts on the management of plaque psoriasis.

Drs Mark Lebwohl and Saakshi Khattri review recent advancements and emerging therapies in development for plaque psoriasis treatment.

MoonLake’s sonelokimab is being evaluated for hidradenitis suppurativa, psoriasis, and psoriatic arthritis.

Loretta Fiorillo, MD, FRCPC, reviews key data points from the phase 3 SPROUT study.

Versus placebo, topical melatonin and rosuvastatin reduced psoriatic plaque severity with a favorable safety profile.

Saakshi Khattri, MD, and Mark Lebwohl, MD, provide insight on the significance of steroid-free treatment options for the management of pediatric patients with plaque psoriasis and address unique considerations and challenges treating patients with skin of color.

Expert dermatologists highlight the use of nonsteroidal topical therapies, roflumilast and tapinarof, for the management of plaque psoriasis.

The merger will focus on advancing Oruka’s portfolio of novel biologics for the treatment of chronic skin diseases.

Learn more about the in-depth topics covered in the March 2024 enhancing psoriasis management supplement of Dermatology Times.

Mark Lebwohl, MD, and Saakshi Khattri, MD, examine the use of spesolimab in various diseases, including generalized pustular psoriasis (GPP), and comment on the use and safety of deucravacitinib.

Drs Mark Lebwohl and Saakshi Khattri review the significance of long-term data of bimekizumab for plaque psoriasis management.

Papp shared insights from the recent STRIDE phase 2 trial, which met all its primary and secondary endpoints. Data was presented at the American Academy of Dermatology Annual Meeting.

Experts in dermatology discuss the use of bimekizumab in clinical practice for plaque psoriasis as well as its off-label use.

Saakshi Khattri, MD, and Mark Lebwohl, MD, share key insights on recent biologic, topical, and oral treatment approvals for the management of plaque psoriasis.

We take a look at various studies exploring the relationship between psoriasis and COVID-19 vaccination, the link between COVID-19 and psoriasis severity, and more.

The expanded approval of Spevigo follows the Chinese National Medical Products Administration’s approval for the injection for the reduction of occurrence of GPP.

A panel of experts discusses tailoring treatment to patient needs, supporting patients' mental health, and considering future directions.

A panel of experts discusses unique needs of patients with skin of color, look at long-term safety and efficacy of emerging oral treatments, and delve into combining topicals with systemic therapies.

Patients with psoriatic disease face an increased risk of cardiovascular disease. Clinicians should consider this when determining management and treatment modalities for patients with psoriasis.

A panel of experts discuss navigating regimen complexity, patient-friendly adherence strategies, addressing steroid phobia and attitudes, and dive into current treatment guidelines.

Mona Shahriari, MD, presented real-world data on the efficacy of IL-23 inhibitors for psoriasis, as well as shared her advice from the Bristol Myers Squibb Women’s Connection Forum.

Lloyd Miller, MD, PhD, delves into the new data demonstrating high rates of skin clearance over 52 weeks in adults with moderate to severe plaque psoriasis.

In an AAD late-breaking research session, Joel Gelfand, MD, MSCE, FAAD, presented in-depth results of the LITE Study.

Psoriasis is linked to a heightened risk of cardiovascular disease, necessitating proactive screening, collaborative care, and consideration of potential impacts of psoriasis treatments on cardiovascular health.

As a pharmacy benefit manager, Livinti will help reduce biologic drug costs for self-funded employees.